Business
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
- Mani Mohindru, Ph.D., Chief Executive Officer of Novasenta, an early-stage biopharmaceutical company, has deep expertise in all phases of drug development,
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"- Mani Mohindru, Ph.D., Chief Executive Officer of Novasenta, an early-stage biopharmaceutical company, has deep expertise in all phases of drug development, finance, strategy and investor relations\n - Renee P. Tannenbaum, Pharm. D., Vice President of Global Partnering at Halozyme, Inc., has extensive experience leading business development and company alliances, commercialization of pipeline drug candidates, and global commercial operations\n\n\nSAN DIEGO, June 10, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced the appointments of Mani Mohindru, Ph.D., and Renee P. Tannenbaum, Pharm.D., as independent members of the Company's Board of Directors. Drs. Mohindru and Tannenbaum are filling the seats of outgoing directors Thomas Adams, Ph.D., and Gary Jacob, Ph.D., on the Company's Board.\n\n \n \n \n \n \n \n\n \n\"We are thrilled to welcome Mani and Renee to our Board of Directors at this exciting and important phase of evolution for Cardiff Oncology,\" said Mark Erlander, Ph.D., board member and chief executive officer of Cardiff Oncology. \"The addition of Mani and Renee is part of an ongoing strategic effort to add relevant leadership experience to our board of directors to support and fulfill the Company's focus on driving future growth, enhancing its corporate governance, and creating additional shareholder value. In her current and prior roles as CEO, chief financial officer and chief strategy officer, Mani has successfully navigated the opportunities and challenges of biotech drug development, financing and investor relations. Renee's expertise in business development and establishing successful strategic partnerships will be invaluable as we continue advancing the development of onvansertib and path toward registration. We are eager to begin working with Mani and Renee and we look forward to benefiting from their insights and counsel. We also extend our sincere thanks to Drs. Adams and Jacobs for their leadership and contributions, which have helped position the Company for continued success.\"\nDr. Mohindru added, \"Joining Cardiff Oncology's Board at this ti...